Allos Therapeutics, Inc. (MM) (NASDAQ:ALTH)
Historical Stock Chart
From Jul 2019 to Jul 2024
![Click Here for more Allos Therapeutics, Inc. (MM) Charts. Click Here for more Allos Therapeutics, Inc. (MM) Charts.](/p.php?pid=staticchart&s=N%5EALTH&p=8&t=15)
Allos Therapeutics Investigator Presents Updated Survival Results
From Phase III REACH Study at San Antonio Breast Cancer Symposium
WESTMINSTER, Colo., Dec. 9 /PRNewswire-FirstCall/ -- Allos Therapeutics, Inc.
(NASDAQ:ALTH) today announced that there will be a presentation on the
Company's lead clinical candidate, EFAPROXYN(TM) (efaproxiral), at the Twenty
Seventh Annual San Antonio Breast Cancer Symposium taking place December 8 - 11
at the Henry B. Gonzalez Convention Center. Dino B. Stea, M.D., Ph.D.,
Director, Radiation Oncology at the Arizona Cancer Center, will give a poster
presentation titled "Efaproxiral (EFAPROXYN(TM)) as an Adjunct to Whole Brain
Radiation Therapy for the Treatment of Brain Metastases Originating from Breast
Cancer: updated survival results of the randomized REACH (RT-009) study" on
Friday, December 10, 2004, 7:00 AM-9:00 AM. The abstract may be accessed
online at http://www.sabcs.org/ at the conclusion of the meeting.
About EFAPROXYN
EFAPROXYN(TM) (efaproxiral) is the first synthetic small molecule designed to
"sensitize" hypoxic (oxygen-deprived) areas of tumors during radiation therapy
by facilitating the release of oxygen from hemoglobin, the oxygen-carrying
protein contained within red blood cells, and increasing the level of oxygen in
tumors. The presence of oxygen in tumors is an essential element for the
effectiveness of radiation therapy in the treatment of cancer. By increasing
tumor oxygenation at the time of treatment, EFAPROXYN has the potential to
enhance the efficacy of standard radiation therapy. Unlike chemotherapeutics
or other radiation sensitizers, EFAPROXYN does not have to cross the blood
brain barrier or enter the tumor to be effective.
About Allos Therapeutics, Inc.
Allos Therapeutics, Inc. is a biopharmaceutical company focused on developing
and commercializing innovative drugs for improving cancer treatments. The
company's lead clinical candidate, EFAPROXYN, is a synthetic small molecule
that has the potential to sensitize hypoxic (oxygen deprived) tumor tissues and
enhance the efficacy of standard radiation therapy. In addition, Allos is
developing PDX (pralatrexate), a novel small molecule cytoxic injectable
antifolate (DHFR inhibitor) that is currently being investigated in patients
with non-small cell lung cancer and non-Hodgkin's lymphoma. For more
information, please visit the company's web site at: http://www.allos.com/.
Safe Harbor Statement
This announcement contains forward-looking statements which are made pursuant
to the safe harbor provisions of the Private Securities Litigation Reform Act
of 1995. Such forward-looking statements include statements concerning the
Company's business plans, objectives, goals and strategies; the Company's
product development plans and activities; the anticipated timing, progress and
results of the Company's clinical trials; the potential safety and efficacy of
the Company's product candidates; the potential market opportunity for the
Company's product candidates; and other statements which are other than
statements of historical facts. In some cases, you can identify
forward-looking statements by terminology such as "may," "will," "should,"
"expects," "intends," "plans," "anticipates," "believes," "estimates,"
"predicts," "projects," "potential," "continue," and other similar terminology
or the negative of these terms, but their absence does not mean that a
particular statement is not forward-looking. Such forward-looking statements
are not guarantees of future performance and are subject to risks and
uncertainties that may cause actual results to differ materially from those
anticipated by these forward-looking statements. Additional information
concerning the risks and uncertainties that may cause such differences is
contained in the "Risk Factors" section of the Company's Annual Report on Form
10-K for the year ended December 31, 2003, as amended, and in the Company's
other periodic reports and filings with the Securities and Exchange Commission,
including the Company's Quarterly Report on Form 10-Q for the quarter ended
September 30, 2004. The Company cautions investors not to place undue reliance
on the forward-looking statements contained in this announcement. All
forward-looking statements are based on information currently available to the
Company on the date hereof, and the Company undertakes no obligation to revise
or update these forward-looking statements to reflect events or circumstances
after the date of this announcement, except as required by law.
DATASOURCE: Allos Therapeutics, Inc.
CONTACT: Jennifer Neiman, Manager, Corporate Communications of Allos
Therapeutics, +1-720-540-5227,
Web site: http://www.sabcs.org/
Web site: http://www.allos.com/